首頁 > 市場調查報告書 > 製藥

處方藥循環系統

市場調查報告書

商品編碼

1738603

全球Warfarin鈉（CAS 129-06-6）市場規模（按類型、應用、區域範圍和預測）

Global Warfarin Sodium (CAS 129-06-6) Market Size By Type (1mg/Tablet, 2.5mg/Tablet), By Application (Hospital Pharmacies, Retail Pharmacies), By Geographic Scope And Forecast

出版日期: 2025年05月12日 | 出版商:

Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

Warfarin林鈉（CAS 129-06-6）市場規模及預測

2024 年華Warfarin鈉 (CAS 129-06-6) 市場規模價值 1976.9 億美元，預計到 2032 年將達到 2833.0 億美元，2026 年至 2032 年的複合年成長率為 4.60%。

Warfarin鈉用於預防血液凝固的日益成長的偏好，催生了醫療保健領域對該產品的需求，從而推動了全球市場的成長。本報告對全球Warfarin鈉 (CAS 129-06-6) 市場進行了全面評估，全面分析了關鍵細分市場、趨勢、市場促進因素、限制因素、競爭格局以及影響市場的關鍵因素。

華法林鈉 (CAS 129-06-6) 市場預計將以 4.60% 的複合年成長率成長，到 2032 年底達到 2833 億美元

華法林鈉的全球市場定義（CAS 129-06-6）

Warfarin鈉是Warfarin的鈉鹽，具有抗凝血活性。 CAS 129-06-6 是化學文摘社為Warfarin林鈉分配的唯一數字識別碼。此藥物常用於治療血栓，例如深層靜脈栓塞症和肺動脈栓塞，以及預防心房顫動、心臟瓣膜疾病或人工心臟瓣膜患者的中風。Warfarin鈉有三種劑型：1 毫克錠劑、2.5 毫克錠劑和 5 毫克錠劑。

華法林鈉通常是口服，但也會靜脈注射。Warfarin鈉可抑制維生素K和維生素K環氧化物還原酶，阻止維生素K環氧化物與其還原形式維生素KH2的循環轉化。維生素KH2是維生素K依賴性蛋白質N端麩胺酸羧基化的輔酶。最常見的副作用是出血，較少見的副作用包括組織損傷部位和紫腳指綜合症。

全球Warfarin鈉（CAS 129-06-6）市場概覽

因此，Warfarin鈉用於預防血液凝固的日益成長的偏好，正在創造醫療保健領域對該產品的需求，從而推動全球市場的成長。然而，Warfarin鈉的多種副作用，例如紅色或棕色尿液、黑便或血便、嚴重頭痛或胃痛、關節痛、嘔吐和嘔血，正在阻礙全球市場的成長。此外，過量攝取攝取Warfarin鈉會導致嚴重血便和比正常情況下更嚴重的月經出血，這預計也會限制市場的成長。

The increasing preference for warfarin sodium for the prevention of blood clotting has created the demand for this product in healthcare, thereby driving the global market growth. The Global Warfarin Sodium (CAS 129-06-6) Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Warfarin Sodium (CAS 129-06-6) Market is estimated to grow at a CAGR of 4.60% & reach US$ 283.3 Bn by the end of 2032

Global Warfarin Sodium (CAS 129-06-6) Market Definition

Warfarin Sodium is the sodium salt form of warfarin, with anticoagulant activity. CAS 129-06-6 is a unique numerical identifier of warfarin sodium assigned by the Chemical Abstracts Service. It is commonly used to treat blood clots such as deep vein thrombosis and pulmonary embolism, and to prevent stroke in people who have atrial fibrillation, valvular heart disease, or artificial heart valves. Warfarin Sodium is categorized into three types: 1 mg/Tablet, 2.5 mg/Tablet, and 5 mg/Tablet.

It is generally taken by mouth, but can also be used by injection into a vein. Warfarin sodium inhibits vitamin K and vitamin K epoxide reductases, thereby obstructing the cyclic interconversion of vitamin K epoxide to its diminished form, vitamin KH2. Vitamin KH2 is a cofactor for the carboxylation of glutamate resting on the N-terminal regions of vitamin K-dependent proteins. The most common side effect is bleeding and less common side effects include areas of tissue damage and purple toes syndrome.

Global Warfarin Sodium (CAS 129-06-6) Market Overview

Thus, the increasing preference for warfarin sodium for the prevention of blood clotting has created the demand for this product in healthcare, thereby driving the global market growth. However, the several side effects of warfarin sodium such as red or brown urine, black or bloody stool, severe headache or stomach pain, joint pain, vomiting, and coughing up blood are hampering the global market growth. Overdose of warfarin sodium also leads to severe blooding or heavier than normal menstrual bleeding, which is also expected to restrict the market growth.

Global Warfarin Sodium (CAS 129-06-6) Market Segmentation Analysis

The Global Warfarin Sodium (CAS 129-06-6) Market Is Segmented On The Basis Of Type, Application, And Geography.

Warfarin Sodium (CAS 129-06-6) Market, By Type

1mg/Tablet

2.5mg/Tablet

5mg/Tablet

Based on Type, the market is segmented into 1mg/Tablet, 2.5mg/Tablet, and 5mg/Tablet. Warfarin, an anticoagulant works by preventing the formation of harmful blood clots. Although it does not dissolve the existing blood clots, it prevents them from growing larger and causing blockages in the blood vessels. It also has a common side effect of Bleeding. Hence it is always advised to consume Warfarin in small amounts. Hence 1mg/Tablets are consumed more and these factors are expected to boost demand for 1mg/Tablets and further propel market growth.

Warfarin Sodium (CAS 129-06-6) Market, By Application

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Based on Application, the market is segmented into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. Hospital pharmacies usually stock a larger variety of medications, including more specialized and investigational medications, than would be feasible in the community setting. Pharmacists in hotels are more trained and equipped. Warfarin can interact with several medicines hence expert advice is always needed. These factors are expected to boost demand and further propel market growth.

Warfarin Sodium (CAS 129-06-6) Market, By Geography

North America
Europe
Asia Pacific
Rest of the world
On the basis of Geography, the Global Warfarin Sodium (CAS 129-06-6) Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. The Europe market is said to be the Fastest Growing Market for Warfarin Sodium (CAS 129-06-6) because there is the highest awareness of deep vein thrombosis and pulmonary embolism and Warfarin is used to prevent stroke prevention, deep vein thrombosis, and pulmonary embolism. The Asia-Pacific place is predicted to develop because of a lack of awareness right now. With the increase in awareness the market will grow too.

Key Players

The "Global Warfarin Sodium (CAS 129-06-6) Market" study report will provide a valuable insight with an emphasis on the global market including some of the major players such as Qilu Pharma, Sine Pharma, Jialin Pharma, Fuda Pharma, Zhongjie Pharma, Amneal Pharma, TEVA, Mylan, and Cipla.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Key Developments

Warfarin Sodium (CAS 129-06-6) Market Key Developments And Mergers
In 2021, Arbutus and Qilu Pharmaceutical Enter into an Exclusive Licensing Agreement and Strategic Partnership.
IN 2018, Qilu ranked top 10 of the Chinese Pharmaceutical Industry in 4 consecutive times.
Cipla was awarded Company of the year 2021 buy the Business Standard.
KEY COMPANIES PROFILED
Qilu Pharma, Sine Pharma, Jialin Pharma, Fuda Pharma, Zhongjie Pharma, Amneal Pharma, TEVA, Mylan, and Cipla.

1 INTRODUCTION OF GLOBAL WARFARIN SODIUM (CAS129-06-6) MARKET

1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL WARFARIN SODIUM (CAS129-06-6) MARKET OUTLOOK

4.1 Overview
4.2 Market Dynamics
- 4.2.1 Drivers
- 4.2.2 Restraints
- 4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis

5 GLOBAL WARFARIN SODIUM (CAS129-06-6) MARKET, BY TYPE

5.1 Overview
5.21mg/Tablet
5.3 2.5mg/Tablet
5.4 5mg/Tablet

6 GLOBAL WARFARIN SODIUM (CAS129-06-6) MARKET, BY APPLICATION

6.1 Overview
6.2 Hospital Pharmacies
6.3 Retail Pharmacies
6.4 Online Pharmacies

7 GLOBAL WARFARIN SODIUM (CAS129-06-6) MARKET, BY GEOGRAPHY

7.1 Overview
7.2 North America
- 7.2.1 U.S.
- 7.2.2 Canada
- 7.2.3 Mexico
7.3 Europe
- 7.3.1 Germany
- 7.3.2 U.K.
- 7.3.3 France
- 7.3.4 Rest of Europe
7.4 Asia Pacific
- 7.4.1 China
- 7.4.2 Japan
- 7.4.3 India
- 7.4.4 Rest of Asia Pacific
7.5 Rest of the World
- 7.5.1 Latin America
- 7.5.2 Middle East and Africa

8 GLOBAL WARFARIN SODIUM (CAS129-06-6) MARKET COMPETITIVE LANDSCAPE

8.1 Overview
8.2 Company Market Ranking
8.3 Key Development Strategies

9 COMPANY PROFILES

9.1 Qilu Pharma
- 9.1.1 Overview
- 9.1.2 Financial Performance
- 9.1.3 Product Outlook
- 9.1.4 Key Developments
9.2 Sine Pharma
- 9.2.1 Overview
- 9.2.2 Financial Performance
- 9.2.3 Product Outlook
- 9.2.4 Key Developments
9.3 Jialin Pharma
- 9.3.1 Overview
- 9.3.2 Financial Performance
- 9.3.3 Product Outlook
- 9.3.4 Key Developments
9.4 Fuda Pharma
- 9.4.1 Overview
- 9.4.2 Financial Performance
- 9.4.3 Product Outlook
- 9.4.4 Key Developments
9.5 Zhongjie Pharma
- 9.5.1 Overview
- 9.5.2 Financial Performance
- 9.5.3 Product Outlook
- 9.5.4 Key Developments
9.6 Amneal Pharma
- 9.6.1 Overview
- 9.6.2 Financial Performance
- 9.6.3 Product Outlook
- 9.6.4 Key Developments
9.7 TEVA
- 9.7.1 Overview
- 9.7.2 Financial Performance
- 9.7.3 Product Outlook
- 9.7.4 Key Developments
9.8 Mylan
- 9.8.1 Overview
- 9.8.2 Financial Performance
- 9.8.3 Product Outlook
- 9.8.4 Key Developments
9.9 Cipla
- 9.9.1 Overview
- 9.9.2 Financial Performance
- 9.9.3 Product Outlook
- 9.9.4 Key Developments